


AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A method for treating schizophrenia in a patient suffering from schizophrenia, without said treatment being accompanied by any extrapyramidal symptoms, which comprises orally administering a once daily dose of 5 mg to 120 mg of the active compound: (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide of the formula (1):



or a pharmaceutically acceptable salt thereof to a patient suffering from schizophrenia, wherein the administration of said active compound improves the positive symptoms of schizophrenia and/or the negative symptoms of schizophrenia and/or the cognitive dysfunction of schizophrenia.

2. **(Previously Presented)** The method of claim 1, wherein the pharmaceutically acceptable salt of said active compound is (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide hydrochloride.

3. – 4. **(Canceled)**

5. **(Previously Presented)** The method of claim 1 or claim 2, wherein 20 mg to 80 mg of said active compound is administered to said patient.

6. – 7. **(Canceled)**


8. **(Previously Presented)** The method of claim 1 or claim 2, wherein said patient is in a chronic stage of schizophrenia, and wherein 20 mg to 80 mg of said active compound is administered to said patient.

9. – 10. **(Canceled)**

11. **(Previously Presented)** The method of claim 8, wherein 50 mg to 80 mg of said active compound is administered to said patient.

12. – 19. **(Canceled)**

20. **(Previously Presented)** A method for treating the positive symptoms and the negative symptoms of schizophrenia in a patient suffering from schizophrenia which comprises orally administering to said patient a preparation comprising a single active compound or a pharmaceutically acceptable salt of said active compound, wherein 5 mg to 120 mg of said active compound is administered once a day to said patient, and wherein said active compound is (1R,2S,3R,4S)-N-[(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide of the formula (1):



21. **(Cancelled)**